Lisa A. Prosser, PhD, MS
- Marilyn Fisher Blanch Research Professor, Pediatrics
- Associate Vice President, Research - Health Sciences, University of Michigan Office of Research
Dr. Prosser's research focuses on measuring the value of childhood health interventions using methods of decision sciences and economics. Current research topics include newborn screening programs, vaccination programs, and methods for valuing family spillover effects of illness. She also uses quantitative survey methods (health utility assessment, conjoint analysis) to measure health-related quality of life and preferences for health interventions.
Dr. Prosser's research evaluating the cost-effectiveness of vaccination programs has been used in setting national vaccine policy for children and adults. Her work with the Evidence Review Group for the Advisory Committee on Heritable Disorders in Newborns and Children using decision science modeling to project long-term health outcomes for proposed newborn screening programs has been used to inform national newborn screening policy decisions. She is currently a member of the evidence review group for the Advisory Committee on Heritable Disorders in Newborns and Children and the ACIP Zoster Working Group.
Dr. Prosser has contributed to faculty development programs at the department, school, and institutional level. Dr. Prosser is the Director of the Susan B. Meister Child Health Evaluation and Research Center. She also serves as Associate Vice President for Research - Health Sciences.
She also os Professor, Department of Pediatrics, University of Michigan Medical School and Professor, Department of Health Management and Policy, University of Michigan School of Public Health.
- PhD, Health Policy (Concentration: Decision Sciences), Harvard University, 2000
- MS, Technology and Policy, Massachusetts Institute of Technology, 1992
- MS, Management, MIT Sloan School of Management, 1992
- BA, Mathematics (Concentration: Operations Research), Cornell University, 1988
Newborn Screening, Vaccination Programs, Decision Sciences, Valuing Family Spillover Effects of Illness, Economic Evaluation, and Cost-Effectiveness Analysis.
VoCHI - Cost-effectiveness analysis of Vaccination to Prevent COVID-19
VoCHI - Eliciting Preferences and Weights for Equity and Efficiency: A Methodological
Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) Evidence
Deriving a Health State Classification System to Measure Health Utilities for Pediatric
Populations Based on the PedsQL
Estimating the economic burden of RSV infection and cost-effectiveness of a hypothetical
Evaluating Health and Economic Outcomes for Preventing Caries Risk in Underserved
Joint Initiative in Vaccine Economics, Phase 6: Estimating the economic burden of
RSV infection and cost-effectiveness of a hypothetical RSV vaccine (JIVE 6)
Joint Initiative in Vaccine Economics, Phase 6: Estimating the quality of life lost
due to COVID-19 illness and adult vs pediatric preferences for COVID-19 vaccination
Prosser LA, Payne K, Rusinak D, Shi P, Messonnier M: Using a discrete choice experiment to elicit time trade-off and willingness-to-pay
amounts for influenza health-related quality of life at different ages. Pharmacoeconomics 31(4): 305-315, 2013. PM23512145
Prosser LA, Lamarand K, Gebremariam A, Wittenberg E: Measuring family HRQoL spillover effects using direct health utility assessment. Medical Decision Making 35(1): 81-93, 2015.PM25057048
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO,
Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG: Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness
Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA 316(10): 1093-103, 2016. PM27623463
Wittenberg E, Prosser LA: Health as a family affair New England Journal of Medicine 374(19): 1804-1806, 2016. PM27168430
Tarini BA, Simon NJ, Payne K, Gebremariam A, Rose A, Prosser LA: An Assessment of
Public Preferences for Newborn Screening Using Best-Worst Scaling. J Pediatr 201: 62-68.e1, 2018. PM30025667
Prosser LA: Defining the Value of Treatments of Rare Pediatric Conditions. JAMA Pediatr 172(12): 1123- 1124, 2018. PM30304346
Neumann PJ, Kim DD, Trikalinos TA, Sculpher MJ, Salomon JA, Prosser LA, Owens DK, Meltzer DO, Kuntz KM, Krahn M, Feeny D, Basu A, Russell LB, Siegel JE,
Ganiats TG, Sanders GD: Future Directions for Cost-effectiveness Analyses in Health and Medicine. Med Decis Making 38(7): 767-777, 2018. PM30248277
Prosser LA, Lam KK, Grosse SD, Casale M, Kemper AR: Using Decision Analysis to Support Newborn Screening Policy Decisions: A Case Study for Pompe Disease. MDM Policy Pract 3(1): 2018. PM30123835/PMC6095138
Prosser LA, Wittenberg E: Advances in Methods and Novel Applications for Measuring Family Spillover Effects
of Illness. Pharmacoeconomics 37(4): 447-450, 2019. PM30915632
Prosser LA, Harpaz R, Rose AM, Gebremariam A, Guo A, Ortega-Sanchez IR, Zhou F, Dooling K: A Cost- Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and
Related Complications: Input for National Recommendations. Ann Intern Med 170(6): 380-388, 2019. PM30776797
Avancena ALV, Prosser LA: Examining Equity Effects of Health Interventions in Cost-Effectiveness Analysis: A
Systematic Review. Value Health 24(1):136-143, 2021.
Richardson JS, Kemper AR, Grosse SD, Lam WKK, Rose AM, Ahmad A, Gebremariam A, Prosser LA: Health and economic outcomes of newborn screening for infantile-onset Pompe disease. Genet Med 23(4):758-766, 2021.